Download PDF
Neuropediatrics 1994; 25(1): 39-41
DOI: 10.1055/s-2008-1071580
Short communication

© Georg Thieme Verlag KG Stuttgart · New York

Etoposide Treatment in Recurrent Medulloblastoma

R.  Boor , A.  Huber , P.  Gutjahr
  • Department of Pediatrics, University of Mainz, Germany
Further Information

Publication History

Publication Date:
15 May 2008 (online)

  PDF Download  Permissions and Reprints

Abstract

Five consecutive patients with recurrent medulloblastoma received etoposide 120 mg/m2 for 5 to 7 days at 2 to 4 week intervals. Three patients with neuroaxis dissemination received additional intrathecal chemotherapy with methotrexate, cytosin arabinoside and prednisone. Toxicity consisted of alopecia and mild neutropenia. Complete response was registered in two patients, partial response in one. Median survival was 19 months with the 3 responders living 6, 30 and 60 + months. Etoposide seems to be an active agent in medulloblastoma.

Key words

Etoposide - Recurrent medulloblastoma

      >